pic1Dr. Constantinos Hadjipanayis, MD, PhD is a Professor of Neurosurgery and Oncological Sciences at the Icahn School of Medicine at Mount Sinai. He serves as Chair of the Department of Neurosurgery at Mount Sinai Union Square/Beth Israel and Director of Neurosurgical Oncology for the Mount Sinai Health System. He is a board-certified neurosurgeon who has devoted his entire career to the treatment of brain tumor patients. He is Director of the Mount Sinai Brain Tumor Nanotechnology Laboratory in the Tisch Cancer Institute where he studies novel therapeutics targeting brain tumors. His Ph.D. graduate training in Biochemistry and Molecular Genetics at the University of Pittsburgh, during his neurosurgery residency, focused on viral gene therapy of brain cancer. Dr. Hadjipanayis has been a tireless brain tumor advocate leading the nonprofit Southeastern Brain Tumor Foundation (SBTF) in the past. He has been the PI of multiple clinical trials and a PI of university-, private foundation-, and NIH-funded grants focused on brain tumors. He has led the development of 5-ALA (Gliolan) and fluorescence-guided surgery (FGS) for malignant brain tumors in the US. In 2011, he was the first in the US to use Gliolan and perform FGS on a brain tumor patient. He led the effort for FDA approval of 5-ALA FGS in June 2017. Most recently, Dr. Hadjipanayis has been leading the development of the first ever voice-controlled, robotic-assisted digital surgical microscope for neurosurgery.